Managing Pruritus in Chronic Liver Disease: An In-depth Narrative Review

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2024 Jun 14

PMID 38872783

Authors

Ana Marenco-Flores

Leandro Sierra

Daniela Goyes

Tamara Kahan

Vilas R Patwardhan

Alan Bonder

Affiliations

Soon will be listed here.

Citing Articles

Overview of Pruritus Management in Patients With Chronic Liver Disease.

Bonder A Gastroenterol Hepatol (N Y). 2024; 20(8):446-448.

PMID: 39205951 PMC: 11348537.

References

Chappell L, Gurung V, Seed P, Chambers J, Williamson C, Thornton J . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ. 2012; 344:e3799. PMC: 3420230. DOI: 10.1136/bmj.e3799. View

Terg R, Coronel E, Sorda J, Munoz A, Findor J . Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002; 37(6):717-22. DOI: 10.1016/s0168-8278(02)00318-5. View

Bergasa N, Alling D, Talbot T, Swain M, Yurdaydin C, Turner M . Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995; 123(3):161-7. DOI: 10.7326/0003-4819-123-3-199508010-00001. View

Chappell L, Bell J, Smith A, Linsell L, Juszczak E, Dixon P . Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019; 394(10201):849-860. PMC: 6739598. DOI: 10.1016/S0140-6736(19)31270-X. View

Hirschfield G, Shiffman M, Gulamhusein A, Kowdley K, Vierling J, Levy C . Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023; 78(2):397-415. PMC: 10344437. DOI: 10.1097/HEP.0000000000000395. View

Bakrania A, Variya B, Madan P, Patel S . Repeated dose 28-day oral toxicity study of DEAE-Dextran in mice: An advancement in safety chemotherapeutics. Regul Toxicol Pharmacol. 2017; 88:262-272. DOI: 10.1016/j.yrtph.2017.07.005. View

Trivedi H, Lizaola B, Tapper E, Bonder A . Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. Am J Med. 2017; 130(6):744.e1-744.e7. DOI: 10.1016/j.amjmed.2017.01.037. View

Al-Dury S, Marschall H . Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. Front Pharmacol. 2018; 9:931. PMC: 6111463. DOI: 10.3389/fphar.2018.00931. View

Di Padova C, Tritapepe R, Rovagnati P, Rossetti S . Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol. 1984; 6(12):773-6. View

10.

Reich A, Heisig M, Phan N, Taneda K, Takamori K, Takeuchi S . Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2011; 92(5):497-501. DOI: 10.2340/00015555-1265. View

11.

Mayo M, Handem I, Saldana S, Jacobe H, Getachew Y, Rush A . Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007; 45(3):666-74. DOI: 10.1002/hep.21553. View

12.

Kremer A, Martens J, Kulik W, Rueff F, Kuiper E, van Buuren H . Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010; 139(3):1008-18, 1018.e1. DOI: 10.1053/j.gastro.2010.05.009. View

13.

Kuiper E, van Erpecum K, Beuers U, Hansen B, Thio H, de Man R . The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010; 52(4):1334-40. DOI: 10.1002/hep.23821. View

14.

Mayo M, Carey E, Smith H, Mospan A, McLaughlin M, Thompson A . Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. Dig Dis Sci. 2022; 68(3):995-1005. PMC: 10406656. DOI: 10.1007/s10620-022-07581-x. View

15.

Xu J, Wang Y, Khoshdeli M, Peach M, Chuang J, Lin J . IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology. 2022; 77(1):20-32. PMC: 9970017. DOI: 10.1002/hep.32599. View

16.

Smith H, de Souza A, Thompson A, McLaughlin M, Dever J, Myers J . Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review. Dig Dis Sci. 2023; 68(6):2710-2730. PMC: 10024020. DOI: 10.1007/s10620-023-07862-z. View

17.

Kowdley K, Bowlus C, Levy C, Akarca U, Alvares-da-Silva M, Andreone P . Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2023; 390(9):795-805. DOI: 10.1056/NEJMoa2306185. View

18.

Medina-Morales E, Barba Bernal R, Gerger H, Goyes D, Trivedi H, Ferrigno B . Pharmacological Therapy of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Clin Gastroenterol. 2023; 57(2):143-152. DOI: 10.1097/MCG.0000000000001797. View

19.

Ostadhadi S, Nikoui V, Haj-Mirzaian A, Kordjazy N, Dehpour A . The role of PPAR-gamma receptor in pruritus. Eur J Pharmacol. 2015; 762:322-5. DOI: 10.1016/j.ejphar.2015.06.009. View

20.

Selim R, Ahn J . Pruritus in Chronic Liver Disease. Clin Liver Dis. 2022; 27(1):47-55. DOI: 10.1016/j.cld.2022.08.011. View